Clover Health (NASDAQ:CLOV) stock is falling on Tuesday after the company announced that changes are coming to its leadership team.
CEO Vivek Garipalli will leaving his role at Clove Health by the end of the year. Current President Andrew Toy will replace the CEO. However, Garipalli will stick around as the Executive Chairman of the company’s board. Currently, he serves as Chairman.
In addition to this news, Clover Health also just released second-quarter results. The release included an adjusted earnings per share (EPS) loss of 22 cents. That’s worse than the -20 cents per share Wall Street had expected.
On the flip side, Q2 revenue did come in at $846.7 million, beating estimates. This was also a massive gain next to revenue of $412.5 million reported in Q2 2021.
Clover Health also reaffirmed its outlook for the full year of 2022. The company expects full-year revenue to range from $3 billion to $3.4 billion. For comparison, Wall Street’s 2022 estimate for Clover’s revenue is $3.31 billion.
Garipalli said the following in the company’s Q2 earnings report.
“Our focus on building a sustainable, intelligent growth engine has led to a reduction in MCRs and improvement in operational efficiencies which we believe is the foundation of our progress toward profitability.”
CLOV stock is down 18% as of Tuesday morning.
We’ve got more of the latest stock news worth knowing about today below!
InvestorPlace is home to all of the most recent stock news for Tuesday! A few examples include why shares of Verona Pharma (NASDAQ:VRNA), Lemonade (NYSE:LMND) and meme stocks are moving today. That news is available at the following links!
More Tuesday Stock Market News
- Why Is Verona Pharma (VRNA) Stock Up 76% Today?
- Lemonade (LMND) Stock Pops 10% After Q2 Earnings
- What Is Going on With Meme Stocks AMC, GME, BBBY Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.